JP2021521154A - 置換ピリジノン含有三環式化合物を調製するための方法 - Google Patents

置換ピリジノン含有三環式化合物を調製するための方法 Download PDF

Info

Publication number
JP2021521154A
JP2021521154A JP2020555350A JP2020555350A JP2021521154A JP 2021521154 A JP2021521154 A JP 2021521154A JP 2020555350 A JP2020555350 A JP 2020555350A JP 2020555350 A JP2020555350 A JP 2020555350A JP 2021521154 A JP2021521154 A JP 2021521154A
Authority
JP
Japan
Prior art keywords
methoxy
methoxypropoxy
salt
solvate
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521154A5 (enExample
Inventor
シュアイ チェン
シュアイ チェン
ブルース ディー． ドーシー
ブルース ディー． ドーシー
ディミタール ビー． ゴチェフ
ディミタール ビー． ゴチェフ
ドゥーヤン グエン
ドゥーヤン グエン
マヘシュ クマール パレラ
マヘシュ クマール パレラ
ガナパティ レッディ パムラパティ
ガナパティ レッディ パムラパティ
Original Assignee
アービュタス バイオファーマ コーポレイション
アービュタス バイオファーマ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アービュタス バイオファーマ コーポレイション, アービュタス バイオファーマ コーポレイション filed Critical アービュタス バイオファーマ コーポレイション
Publication of JP2021521154A publication Critical patent/JP2021521154A/ja
Publication of JP2021521154A5 publication Critical patent/JP2021521154A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2020555350A 2018-04-12 2019-04-11 置換ピリジノン含有三環式化合物を調製するための方法 Pending JP2021521154A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862656605P 2018-04-12 2018-04-12
US62/656,605 2018-04-12
US201862700048P 2018-07-18 2018-07-18
US62/700,048 2018-07-18
PCT/US2019/027004 WO2019200109A1 (en) 2018-04-12 2019-04-11 Methods for preparing substituted pyridinone-containing tricyclic compounds

Publications (2)

Publication Number Publication Date
JP2021521154A true JP2021521154A (ja) 2021-08-26
JP2021521154A5 JP2021521154A5 (enExample) 2022-03-25

Family

ID=68163316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555350A Pending JP2021521154A (ja) 2018-04-12 2019-04-11 置換ピリジノン含有三環式化合物を調製するための方法

Country Status (9)

Country Link
US (1) US11505551B2 (enExample)
EP (1) EP3773584A4 (enExample)
JP (1) JP2021521154A (enExample)
KR (1) KR20200142529A (enExample)
CN (1) CN112839654A (enExample)
AU (1) AU2019252441A1 (enExample)
CA (1) CA3096687A1 (enExample)
TW (1) TW202010499A (enExample)
WO (1) WO2019200109A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128044B2 (en) 2018-08-28 2024-10-29 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5697163B2 (ja) * 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
WO2017016960A1 (en) * 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
JP2017504633A (ja) * 2014-01-30 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
WO2018022282A1 (en) * 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78491B (enExample) 1982-03-24 1984-09-27 Nat Res Dev
JPS60197684A (ja) 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔ａ〕キノリジン誘導体およびその塩
ITFI970193A1 (it) 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US8063037B2 (en) 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
EP3325477B1 (en) 2015-07-21 2019-05-01 H. Hoffnabb-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN109071447B (zh) 2016-02-19 2022-04-22 诺华股份有限公司 四环吡啶酮化合物作为抗病毒剂
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
CN107759585A (zh) 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
CN106810548B (zh) 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5697163B2 (ja) * 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
JP2017504633A (ja) * 2014-01-30 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
WO2017016960A1 (en) * 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2018022282A1 (en) * 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAIRE-MARIE MARTINEZ ET AL.: "A convenient biomimetic synthesis of optically active putative neurotoxic metabolites of MDMA ("ecs", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 18, JPN7023000624, 2012, pages 3739 - 3748, ISSN: 0004987225 *
SALOME LLABRES ET AL.: "Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor s", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 81, JPN7023000626, 2014, pages 35 - 46, ISSN: 0004987227 *
VALENTINE G. NENAJDENKO ET AL.: "A new convenient approach to chiral β-aryl(heteroaryl)alkylamines", TETRAHEDRON: ASYMMETRY, vol. 12, no. 18, JPN7023000623, 2001, pages 2517 - 2527, ISSN: 0004987228 *
YASUHIRO ISHIDA ET AL.: "Tunable Chiral Reaction Media Based on Two-Component Liquid Crystals: Regio-, Diastereo-, and Enanti", J. AM. CHEM. SOC., vol. 132, no. 49, JPN7023000625, 2010, pages 17435 - 17446, ISSN: 0004987226 *

Also Published As

Publication number Publication date
WO2019200109A1 (en) 2019-10-17
US20210032246A1 (en) 2021-02-04
EP3773584A1 (en) 2021-02-17
EP3773584A4 (en) 2022-01-05
TW202010499A (zh) 2020-03-16
US11505551B2 (en) 2022-11-22
AU2019252441A1 (en) 2020-10-22
KR20200142529A (ko) 2020-12-22
CN112839654A (zh) 2021-05-25
CA3096687A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
TWI471323B (zh) 有效ｈｃｖ抑制劑之結晶型式
CN107759602B (zh) 含有共轭联烯结构的化合物、其药物组合物和用途
CN112105610A (zh) 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
CN110959008A (zh) 青霉素结合蛋白抑制剂
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
CN104736532A (zh) 改进的生产5-(2,6-二-4-吗啉-4-嘧啶)-4-三氟甲基吡啶-2-胺的方法
CN107663190B (zh) 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
JP2023103364A (ja) 化合物、その薬学的に許容される塩又は立体異性体、及びその使用
US20250243211A1 (en) Processes and intermediates for producing diazaspiro lactam compounds
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
CN116406362A (zh) 用于治疗和预防乙型肝炎病毒感染的螺[3.3]庚烷衍生物
US11505551B2 (en) Methods for preparing substituted pyridinone-containing tricyclic compounds
US20170246198A1 (en) Process for Making Nucleoside Phosphoramidate Compounds
TW202412764A (zh) 經取代之１－芳基－１＇－雜芳基化合物及經取代之１，１＇－聯雜芳基化合物及其類似物的合成
CN114364671B (zh) 用于制备嘧啶基联吡啶化合物的方法以及用于其的中间体
JP7154659B2 (ja) 縮合環含有化合物、その使用及びそれを含む医薬組成物
CN119059970B (zh) 一种btk抑制剂药物中间体的制备方法
CN109535060B (zh) 一种刺猬通路抑制剂及其制备方法和应用
EP3448861B1 (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
TW201943707A (zh) 經取代的二氫茚-4-甲醯胺化合物的製備方法
HK1257427B (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
AU2022245255A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)-carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
HK40067636A (en) Substituted 3,4-dihydroquinazoline for the treatment and prophylaxis of hepatitis b virus infection
CN114502538A (zh) 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉
TW201925178A (zh) 阿卡替尼（acalabrutinib）之製造方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230830